Cargando…

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)

Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed evolving from symptom‐based strategies to others aiming to move patients to low‐risk conditions. Endothelin‐1 (ET‐1) receptor antagonists emerged as specific‐PAH drugs th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aldalaan, Abdullah M., Saleemi, Sarfraz A., Weheba, Ihab, Abdelsayed, Abeer, Aleid, Maha M., Alzubi, Fatima, Zaytoun, Hamdeia, Alharbi, Nadeen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063971/ https://www.ncbi.nlm.nih.gov/pubmed/35514768 http://dx.doi.org/10.1002/pul2.12083

Ejemplares similares

Chronic thromboembolic pulmonary hypertension in Saudi Arabia: preliminary results from the SAUDIPH registry
por: Aldalaan, Abdullah M., et al.
Publicado: (2020)

Genetic basis of pulmonary arterial hypertension: a prospective study from a highly inbred population
por: Aldalaan, Abdullah M., et al.
Publicado: (2021)

Superior vena cava stenting in IgG4-associated mediastinal fibrosis
por: Khalid, Mohammed, et al.
Publicado: (2020)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Li, Jie, et al.
Publicado: (2022)

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
por: Iglarz, Marc, et al.
Publicado: (2015)

Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study
por: Corallo, Claudio, et al.
Publicado: (2016)

Nocardiosis at an Organ Transplant Center in Saudi Arabia: 15 years' experience
por: Weheba, Ihab, et al.
Publicado: (2021)

Clinical outcome and survival in 30 pulmonary hypertension patients with high severity indices and advanced functional class
por: Khalid, Mohammed, et al.
Publicado: (2019)

Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes
por: Lepist, Eve-Irene, et al.
Publicado: (2014)

Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report
por: Conca, Walter, et al.
Publicado: (2020)

Anti-IgE therapy for asthma: an audit at a tertiary care centre in Saudi Arabia
por: Weheba, Ihab Mokhtar, et al.
Publicado: (2018)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Bosentan monohydrate
por: Kaur, Manpreet, et al.
Publicado: (2012)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice
por: Imhof, Anne-Katja, et al.
Publicado: (2011)

Portopulmonary hypertension
por: Saleemi, Sarfraz
Publicado: (2010)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia
por: Saleemi, Sarfraz
Publicado: (2014)

Studies on the Vitrified and Cryomilled Bosentan
por: Minecka, Aldona, et al.
Publicado: (2021)

Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study
por: Di Scala, Lilla, et al.
Publicado: (2022)

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
por: Jung, Hae Ok
Publicado: (2018)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Efficacy and safety of macitentan for pulmonary hypertension: A meta‐analysis
por: Du, Dan, et al.
Publicado: (2023)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
por: Onda, Naomi, et al.
Publicado: (2014)

The effect of Bosentan on healing of colonic anastomosis
por: Cetinkaya, Ziya, et al.
Publicado: (2006)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
por: Monaco, Thomas J, et al.
Publicado: (2016)

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series
por: Mathijssen, H., et al.
Publicado: (2020)

Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
por: Pawar, Ravindra, et al.
Publicado: (2009)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Portopulmonary hypertension
por: Saleemi, Sarfraz, et al.
Publicado: (2014)

Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia
por: Khalid, Mohammad, et al.
Publicado: (2014)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

The use of Macitentan in Fontan circulation: a case report
por: Demetriades, Polyvios, et al.
Publicado: (2017)

Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan
por: De Haro, Joaquin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ilak5jpcoisn2bsoosg2vmderl